Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.
Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, Ertl LS, Zeng Y, Powers JP, Pennell AM, Bekker P, Schall TJ, Jaen JC. Dairaghi DJ, et al. Among authors: zhang p. Clin Pharmacol Ther. 2011 May;89(5):726-34. doi: 10.1038/clpt.2011.33. Epub 2011 Mar 30. Clin Pharmacol Ther. 2011. PMID: 21451509 Clinical Trial.
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.
Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L, Brown JM. Walters MJ, et al. Among authors: zhang p. Br J Cancer. 2014 Mar 4;110(5):1179-88. doi: 10.1038/bjc.2013.830. Epub 2014 Jan 14. Br J Cancer. 2014. PMID: 24423923 Free PMC article.
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ. Bekker P, et al. Among authors: zhang p. PLoS One. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646. eCollection 2016. PLoS One. 2016. PMID: 27768695 Free PMC article. Clinical Trial.
Structural basis of ligand interaction with atypical chemokine receptor 3.
Gustavsson M, Wang L, van Gils N, Stephens BS, Zhang P, Schall TJ, Yang S, Abagyan R, Chance MR, Kufareva I, Handel TM. Gustavsson M, et al. Among authors: zhang p. Nat Commun. 2017 Jan 18;8:14135. doi: 10.1038/ncomms14135. Nat Commun. 2017. PMID: 28098154 Free PMC article.
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.
Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC. Luo Y, et al. Among authors: zhang p. Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30. Int J Cancer. 2018. PMID: 29277895 Free PMC article.
31,129 results
You have reached the last available page of results. Please see the User Guide for more information.